MLchartDataset catalogue

Vonjo

Term · Oncology and biomedicine · MLC-T-ONC-009314

A drug used to treat adults with intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. It is used in patients who have a very low blood platelet count. It is also being studied in the treatment of other conditions and some types of cancer. Vonjo blocks JAK2 and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of kinase inhibitor. Also called pacritinib citrate.

Table 1. Record
IdentifierMLC-T-ONC-009314
FieldOncology and biomedicine
Synonymspacritinib citrate
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-009314",
  "term": "Vonjo",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults with intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. It is used in patients who have a very low blood platelet count. It is also being studied in the treatment of other conditions and some types of cancer. Vonjo blocks JAK2 and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of kinase inhibitor. Also called pacritinib citrate.",
  "synonyms": [
    "pacritinib citrate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/vonjo/"
}

Record 17,335 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.